Kelzy Pr (Dienogest, Ethinylestradiol | Lactose)

Kelzy Pr, a combined oral contraceptive, is indicated for hormonal management of reproductive health.

• Pregnancy prevention: provides reliable contraception to avoid unintended pregnancy.
• Menstrual cycle regulation: helps establish regular menstrual bleeding patterns.
• Management of hormone‑related menstrual disorders: reduces symptoms such as heavy bleeding and dysmenorrhea.

• Dienogest is a progestogenic agent that binds to progesterone receptors, suppressing the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). Ethinylestradiol provides estrogenic activity that stabilises the endometrium and enhances negative feedback on the hypothalamic‑pituitary axis. Together they inhibit ovulation, thicken cervical mucus and alter the endometrial lining, preventing fertilisation and implantation. The combined hormonal effect maintains a consistent plasma concentration that supports contraceptive efficacy throughout the monthly cycle.

Kelzy Pr may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Nausea: mild stomach upset often occurring early in treatment.
• Breast tenderness: temporary swelling or discomfort of the breasts.
• Headache: mild to moderate headaches.
• Spotting or breakthrough bleeding: irregular light bleeding between periods.
• Weight change: slight increase or decrease in body weight.
• Mood changes: mild emotional fluctuations or irritability.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins or lungs.
• Arterial thrombosis: increased risk of heart attack or stroke.
• Severe hypertension: sudden high blood pressure.
• Liver dysfunction: abnormal liver enzyme elevations.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Visual disturbances: sudden changes in vision or eye pain.

Before prescribing Kelzy Pr, healthcare professionals should consider several precautionary measures to ensure patient safety.

• Assess cardiovascular risk: evaluate history of thrombosis, hypertension, or smoking.
• Review hepatic function: avoid use in severe liver disease.
• Screen for contraindicated medications: consider interactions with enzyme inducers.
• Counsel on smoking status: advise cessation, especially in women over 35.
• Monitor for signs of thromboembolism: educate patients on leg pain, chest discomfort, or sudden shortness of breath.
• Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Kelzy Pr can interact with other medicines, altering its effectiveness or increasing risk of adverse events.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce contraceptive efficacy.
• Other estrogen‑containing products (e.g., hormone replacement therapy): increase risk of thrombotic events.
• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., ketoconazole): can increase hormone plasma levels.
• Certain antidepressants (e.g., SSRIs): may exacerbate mood‑related side effects.
• Diuretics (e.g., thiazides): may affect fluid balance and blood pressure.